About Penta
Who we are
Diversity and Inclusion
Our Network
Penta Foundation Italy
Penta ID Innovation
Annual reports
Our Activities
News & Events
News
Press center
Penta Newsletter
Stories
Scientific Views
Penta Aperitivo Webinars
Publications
Contact us
Work with us
Vacancies
Call for services
Brighter Future Award
Archivio
Invasive ventilation in children during COVID-19 pandemic
Family-centered care in the PICU during the COVID-19 pandemic
The end of the pandemic
A comparison of five paediatric dosing guidelines for antibiotics
The bat, the pangolin and the city: a tale of COVID-19
Interim pharmacokinetic analysis of a multi-centre randomised open label phase IIb study in neonates to validate the meta-analysis population pharmacokinetic model used to simulate an optimised dosing regimen in neonates and infants aged < 90 days: the NeoVanc trial
An optimised dosing regimen vs. a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in infants less than 90 days: the NeoVanc trial
Respiratory pathogens detected in children with community-acquired sepsis-like syndrome in 6 European countries
Aetiology and outcome of children hospitalised for acute respiratory tract infections in Europe: findings from a multi-country combined case-control and cohort study
Application of WISCA (Weighted Incidence Syndromic Combination Antibiogram) to guide empiric therapy in oncological paediatric patients with febrile neutropenia
Antibiotic treatment for paediatric outpatients with community-acquired pneumonia: findings from 10 years of prescribing habits in Italy
Ethics in PIC in the time of COVID
Prof. Sarah Walker leads the CIS study on COVID-19
Overview on COVID-19 outbreak
Tribute to Lynda Harper
RECOVER enrolls first patients in its COVID-19 studies!
The role of ECMO in the current pandemic – Experience so far
An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial